Asset Details
Do you wish to reserve the book?
Duloxetine in the prevention of relapse of major depressive disorder: Double-blind placebo-controlled study
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Duloxetine in the prevention of relapse of major depressive disorder: Double-blind placebo-controlled study
Do you wish to request the book?
Duloxetine in the prevention of relapse of major depressive disorder: Double-blind placebo-controlled study
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Duloxetine in the prevention of relapse of major depressive disorder: Double-blind placebo-controlled study
2006
Overview
Relapse rates may be as high as 50% in people with major depressive disorder (MDD) previously treated to remission.
Duloxetine, an inhibitor of serotonin and noradrenaline reuptake that is licensed in Europe, the USA and elsewhere for the treatment of depressive episodes, was evaluated with regard to its efficacy, safety and tolerability in the prevention of relapse of MDD.
Adult out-patients with MDD received duloxetine (60 mg daily) for 12 weeks (n=533). Patients who responded to the drug were then randomised to duloxetine(60 mg daily)(n=136) or or placebo placebo (n=142) for 26 weeks. The primary measure of efficacy was time to relapse.
Patients who received duloxetine (60 mg daily) experienced significantly longer times to relapse of MDD, and better efficacy, global well-being, and quality-of-life outcomes compared with patients who received placebo. It should be noted that adverse events which occur in discontinuation may mimic some signs of depressive relapse, and were not specifically elicited in this study.
Duloxetine (60 mg daily) is effective in the prevention of relapse of MDD during continuation treatment.
Publisher
RCP,Cambridge University Press
